Clinical trial Recruiting at 2 sites Observational Ages 18 and up

Salivary biomarker panel to predict periodontal health over 2 years

Official title: LONGITUDINAL FOLLOW-UP STUDY TO DETERMINE THE PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED PATIENTS

Run by Universidad Complutense de Madrid · NCT07167771 · Data updated 2026-11-12

A 2-year observational study will test whether a panel of saliva biomarkers can predict periodontal health status in adults with varying periodontal conditions.

More Periodontal Diseases trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorUniversidad Complutense de Madrid
Academic / other
Locations2 sites (Madrid and 1 other locations)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedOctober 2027
Study endsOctober 2028
Registry record updatedJune 29, 2026
Trial IDNCT07167771 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) previously enrolled in the referenced cross-sectional study and diagnosed across the periodontal health spectrum (healthy, gingivitis, treated periodontitis, and stages I–IV periodontitis) who can commit to 1- and 2-year follow-ups.

Probably not a fit

Individuals unable to attend follow-up visits or whose conditions fall outside the specified diagnostic groups may not benefit from this observational tracking.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a longitudinal, observational follow-up study at the University Complutense de Madrid. Adults previously in a cross-sectional study will be re-evaluated at 1 and 2 years to see if salivary biomarkers correlate with changes in periodontal health. Participants will be categorized by the 2018 periodontal disease classifications and receive comprehensive medical measurements at each visit. No intervention will be given; the study relies on biomarker profiling and clinical follow-up to identify predictive patterns. The aim is to determine if saliva tests can help forecast periodontal status over time.

Why it matters

Potential benefit: If successful, saliva biomarker testing could help clinicians predict periodontal progression or stability, enabling earlier and more targeted care.

How similar studies have gone: Previous研究 in this area have shown potential for salivary biomarkers to reflect periodontal status, but predictive validity over time remains an area of active investigation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants from the cohort involved in the previous cross-sectional study (code 23/481-E).
* Adults (≥ 18-year-old)
* Being able to sign an informed consent form
* Willing to participate in this observational investigation
* Diagnosed as periodontally healthy, gingivitis, treated periodontitis patient (stable / unstable), periodontitis stages I \& II, or periodontitis stages III and IV (Papapanou et al. 2023) in the previous cross-sectional study (code 23/481-E)

Exclusion Criteria:

* Patients fitting to all the above inclusion criteria will be excluded from the study if unable to attend to the study-related procedures.

Where it's running

  • Faculty of Dentistry, University Complutense of Madrid (UCM)
    Madrid, Spain
    Recruiting
  • Faculty of Dentistry, University Complutense of Madrid (UCM)
    Madrid, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.